Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

被引：2
|
作者：
Cella, David [1 ]
McKendrick, Jan [2 ]
Davis, Harrison [2 ]
Vij, Ravi [3 ]
Chen, Clara [4 ]
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
[2] PRMA Consulting Ltd, Fleet, England
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Bristol Myers Squibb, Princeton, NJ USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122668
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2190
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
    Dimopoulos, Meletios A.
    Weisel, Katja
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Anderson, Kenneth C.
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Ganetsky, Alex
    Jou, Ying-Ming
    McKiver, Mihaela Popa
    Singhal, Anil K.
    Richardson, Paul G.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E15 - E16
  • [2] Phase 3 ELOQUENT-2 study: extended 4-year follow-up of Elotuzumab plus lenalidomide/ dexamethasone vs lenalidomide/ dexamethasone in relapsed/ refractory multiple myeloma
    Weisel, K.
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 35 - 35
  • [3] PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    Weisel, K.
    [J]. HAEMATOLOGICA, 2017, 102 : 167 - 168
  • [4] ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Lonial, S.
    Palumbo, A.
    White, D.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Moreau, P.
    Mateos, M. -V.
    Magen, H.
    Belch, A.
    Reece, D.
    Beksac, M.
    Spencer, A.
    Oakervee, H.
    Taniwaki, M.
    Roellig, C.
    Wu, K. L.
    Singhal, A.
    San Miguel, J.
    Matsumoto, M.
    Katz, J.
    Bleickardt, E.
    Poulart, V.
    Richardson, P.
    [J]. HAEMATOLOGICA, 2015, 100 : 173 - 173
  • [5] ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE/DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (ELOQUENT-2): A 3-YEAR SAFETY UPDATE.
    Doss, Deborah
    Colson, Kathleen
    Gleason, Charise
    Richardson, Paul
    Lonial, Sagar
    [J]. ONCOLOGY NURSING FORUM, 2016, 43 (02) : 64 - 64
  • [6] Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study
    Weisel, Katja
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Cocks, Kim
    Espensen, Ashlee
    Popa-McKiver, Mihaela
    Chen, Clara
    Cavo, Michele
    [J]. BLOOD, 2018, 132
  • [7] Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial
    Ohashi, Kazuteru
    Suzuki, Kenshi
    Sunami, Kazutaka
    Iida, Shinsuke
    Okamoto, Shinichiro
    Handa, Hiroshi
    Matsue, Kosei
    Miyoshi, Masafumi
    Bleickardt, Eric
    Matsumoto, Morio
    Taniwaki, Masafumi
    [J]. BLOOD, 2016, 128 (22)
  • [8] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Iida, Shinsuke
    Nagai, Hirokazu
    Kinoshita, Gen
    Miyoshi, Masafumi
    Robbins, Michael
    Pandya, Dimple
    Bleickardt, Eric
    Chou, Takaaki
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 326 - 334
  • [9] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Shinsuke Iida
    Hirokazu Nagai
    Gen Kinoshita
    Masafumi Miyoshi
    Michael Robbins
    Dimple Pandya
    Eric Bleickardt
    Takaaki Chou
    [J]. International Journal of Hematology, 2017, 105 : 326 - 334
  • [10] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Spencer, Andrew
    Attal, Michael
    Prince, H. Miles
    Harousseau, Jean-Luc
    Dmoszynska, Anna
    San Miguel, Jesus
    Hellmann, Andrzej
    Facon, Thierry
    Foa, Robin
    Corso, Alessandro
    Masliak, Zvenyslava
    Olesnyckyj, Marta
    Yu, Zhinuan
    Patin, John
    Zeldis, Jerome B.
    Knight, Robert D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21): : 2123 - 2132
12345